Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice TargetHot
Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $758 to $779.
Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $758 to $779.